tiprankstipranks
Benitec Biopharma (DE:BJ9)
NASDAQ:BJ9
Germany Market
BJ9
Benitec Biopharma
RESEARCH TOOLSreports

Benitec Biopharma (BJ9) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

BJ9 Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Benitec
Biopharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BJ9 Stock 12 Month Forecast

Average Price Target

€21.88
▲(614.95% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Benitec Biopharma in the last 3 months. The average price target is €21.88 with a high forecast of €28.00 and a low forecast of €15.75. The average price target represents a 614.95% change from the last price of €3.06.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","29":"€29","8.75":"€8.75","15.5":"€15.5","22.25":"€22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28.0032624,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.87754875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€21.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.751835100000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€15.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,4.978712492307692,6.897424984615385,8.816137476923076,10.734849969230769,12.653562461538462,14.572274953846154,16.490987446153845,18.40969993846154,20.32841243076923,22.24712492307692,24.165837415384615,26.084549907692306,{"y":28.0032624,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,4.50750375,5.955007500000001,7.40251125,8.850015,10.29751875,11.745022500000001,13.192526250000002,14.640030000000001,16.08753375,17.5350375,18.98254125,20.430045,{"y":21.87754875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,4.036295007692308,5.012590015384616,5.988885023076923,6.965180030769231,7.9414750384615385,8.917770046153846,9.894065053846154,10.870360061538461,11.84665506923077,12.822950076923078,13.799245084615386,14.775540092307693,{"y":15.751835100000001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€28.00Average Price Target€21.88Lowest Price Target€15.75
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on DE:BJ9
Debjit Chattopadhyay
Guggenheim
Guggenheim
―
Hold
―
Downgraded
06/10/26
Benitec Biopharma downgraded to Neutral from Buy at GuggenheimBenitec Biopharma downgraded to Neutral from Buy at Guggenheim
H.C. Wainwright Analyst forecast on DE:BJ9
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€28
Buy
815.14%
Upside
Reiterated
05/26/26
Benitec Biopharma: Buy Rating Reiterated on Promising BB-301 Data and Solid Cash Runway; $32 Price Target Maintained
Leerink Partners Analyst forecast on DE:BJ9
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€15.75
Buy
414.77%
Upside
Reiterated
05/15/26
Leerink Partners Keeps Their Buy Rating on Benitec Biopharma (BNTC)
TD Cowen Analyst forecast on DE:BJ9
Ritu Baral
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/14/26
Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia
Evercore ISI Analyst forecast on DE:BJ9
Cory Kasimov
Evercore ISI
Evercore ISI
€21.88
Buy
614.95%
Upside
Initiated
05/12/26
Benitec Biopharma initiated with an Outperform at Evercore ISIBenitec Biopharma initiated with an Outperform at Evercore ISI
Citizens JMP Analyst forecast on DE:BJ9
Silvan Tuerkcan
Citizens JMP
Citizens JMP
€17.5→€19.25
Buy
529.16%
Upside
Reiterated
11/04/25
Benitec Biopharma price target raised to $22 from $20 at Citizens JMPBenitec Biopharma price target raised to $22 from $20 at Citizens JMP
Piper Sandler Analyst forecast on DE:BJ9
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€26.25
Buy
757.94%
Upside
Reiterated
09/24/25
Piper Sandler Sticks to Its Buy Rating for Benitec Biopharma (BNTC)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on DE:BJ9
Debjit Chattopadhyay
Guggenheim
Guggenheim
―
Hold
―
Downgraded
06/10/26
Benitec Biopharma downgraded to Neutral from Buy at GuggenheimBenitec Biopharma downgraded to Neutral from Buy at Guggenheim
H.C. Wainwright Analyst forecast on DE:BJ9
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€28
Buy
815.14%
Upside
Reiterated
05/26/26
Benitec Biopharma: Buy Rating Reiterated on Promising BB-301 Data and Solid Cash Runway; $32 Price Target Maintained
Leerink Partners Analyst forecast on DE:BJ9
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€15.75
Buy
414.77%
Upside
Reiterated
05/15/26
Leerink Partners Keeps Their Buy Rating on Benitec Biopharma (BNTC)
TD Cowen Analyst forecast on DE:BJ9
Ritu Baral
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/14/26
Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia
Evercore ISI Analyst forecast on DE:BJ9
Cory Kasimov
Evercore ISI
Evercore ISI
€21.88
Buy
614.95%
Upside
Initiated
05/12/26
Benitec Biopharma initiated with an Outperform at Evercore ISIBenitec Biopharma initiated with an Outperform at Evercore ISI
Citizens JMP Analyst forecast on DE:BJ9
Silvan Tuerkcan
Citizens JMP
Citizens JMP
€17.5→€19.25
Buy
529.16%
Upside
Reiterated
11/04/25
Benitec Biopharma price target raised to $22 from $20 at Citizens JMPBenitec Biopharma price target raised to $22 from $20 at Citizens JMP
Piper Sandler Analyst forecast on DE:BJ9
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€26.25
Buy
757.94%
Upside
Reiterated
09/24/25
Piper Sandler Sticks to Its Buy Rating for Benitec Biopharma (BNTC)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Benitec Biopharma

3 Months
Yasmeen RahimiPiper Sandler
Success Rate
7/9 ratings generated profit
78%
Average Return
+10.87%
Copying Yasmeen Rahimi's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +10.87% per trade.
1 Year
Yasmeen RahimiPiper Sandler
Success Rate
7/9 ratings generated profit
78%
Average Return
+26.76%
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +26.76% per trade.
2 Years
Silvan TuerkcanCitizens JMP
Success Rate
18/23 ratings generated profit
78%
Average Return
+116.77%
Copying Silvan Tuerkcan's trades and holding each position for 2 Years would result in 78.26% of your transactions generating a profit, with an average return of +116.77% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BJ9 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
3
2
5
3
3
Buy
1
1
1
1
1
Hold
0
0
1
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
3
7
6
6
In the current month, BJ9 has received 4 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BJ9 average Analyst price target in the past 3 months is 21.88.
Each month's total comprises the sum of three months' worth of ratings.

BJ9 Financial Forecast

BJ9 Earnings Forecast

Next quarter’s earnings estimate for BJ9 is -€0.24 with a range of -€0.31 to -€0.22. The previous quarter’s EPS was -€0.21. BJ9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year BJ9 has Performed in-line its overall industry.
Next quarter’s earnings estimate for BJ9 is -€0.24 with a range of -€0.31 to -€0.22. The previous quarter’s EPS was -€0.21. BJ9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year BJ9 has Performed in-line its overall industry.

BJ9 Sales Forecast

Next quarter’s sales forecast for BJ9 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. BJ9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year BJ9 has Performed in-line its overall industry.
Next quarter’s sales forecast for BJ9 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. BJ9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year BJ9 has Performed in-line its overall industry.

BJ9 Stock Forecast FAQ

What is DE:BJ9’s average 12-month price target, according to analysts?
Based on analyst ratings, Benitec Biopharma’s 12-month average price target is 21.88.
    What is DE:BJ9’s upside potential, based on the analysts’ average price target?
    Benitec Biopharma has 614.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Benitec Biopharma a Buy, Sell or Hold?
          Benitec Biopharma has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Benitec Biopharma’s share price target?
            The average share price target for Benitec Biopharma is 21.88. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €28.00 ,and the lowest forecast is €15.75. The average share price target represents 614.95% Increase from the current price of €3.06.
              What do analysts say about Benitec Biopharma?
              Benitec Biopharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Benitec Biopharma?
                To buy shares of DE:BJ9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.